Reappraisal of immunohistochemical profiling of special histological types of breast carcinomas: A study of 121 cases of eight different subtypes

Journal of Clinical Pathology

Volumn 65, Issue 12, 2012, Pages 1066-1071

  Alvarenga, César Augusto ^a,b   Paravidino, Paula Itagyba ^a,b   Alvarenga, Marcelo ^b   Gomes, Madalena ^a   Dufloth, Rozany ^c   Zeferino, Luiz Carlos ^d   Vassallo, José ^d,e   Schmitt, Fernando C ^a,f  

^a UNIVERSITY OF PORTO   (Portugal)

^b Instituto de Patologia de Campinas   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e A C CAMARGO CANCER CENTER   (Brazil)

^f University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CADHERIN; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P63;

ADULT; AGED; APOCRINE CARCINOMA; ARTICLE; BREAST APOCRINE CARCINOMA; BREAST CARCINOMA; BREAST INVASIVE PAPILLARY CARCINOMA; BREAST MEDULLARY CARCINOMA; BREAST METAPLASTIC CARCINOMA; BREAST MIXED CARCINOMA; BREAST MUCINOUS CARCINOMA; BREAST TUBULAR CARCINOMA; BREAT MICROPAPILLARY CARCINOMA; CANCER CLASSIFICATION; CANCER INVASION; CELL PROLIFERATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CADHERINS; CARCINOMA; ESTROGEN RECEPTOR ALPHA; FEMALE; FOCAL EPITHELIAL HYPERPLASIA; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84870058411     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200885     Document Type: Article

References (55)

1. Botha JL, Bray F, Snkila R, et al. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003;39:1718-29. (Pubitemid 36897609)
2. Bertolo C, Guerrero D, Vicente F, et al. Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am J Clin Pathol 2008;130:414-24.
3. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009;6:718-30.
4. Reis-Filho JS, Lakhani SR. Breast cancer special types: why bother? J Pathol 2008;216:394-8.
5. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol 2005;205:248-54.
6. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007;7:659-72. (Pubitemid 47327411)
7. Ellis P, Schnitt SJ, Sastre-Garau, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, eds. WHO classification of tumours. pathology and genetics of tumours of the breast and female genital organs. Lyon: Lyon Press, 2003:13-59.
8. Correa Geyer FC, Reis-Filho JS. Microarray-based gene expression profiling as a clinical tool for breast cancer managment: are we there yet? Int J Surg Pathol 2008;17:285-302.
9. Shin HJ, Lim HH, Kim SM, et al. Pure and mixed tubular carcinoma of the breast: mammographic and sonographic differential features. Korean J Radiol 2007;8:103-10.
10. Wynveen C, Nehhozina T, Akram M, et al. Intracystic papillary carcinoma of the breast: an in situ or invasive tumour? Results of immunohistochemical analysis of clinical follow-up. Am J Surg Pathol 2011;35:1-14.
11. Calderaro J, Espie M, Duclos J, et al. Breast intracystic papillary carcinoma: an update. Breast J 2009;15:639-44.
12. Collins LC, Carlo VP, Hwang H, et al. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol 2006;30:1002-7. (Pubitemid 44264950)
13. Esposito NN, Dabs DJ, Bhargava R. Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases. Am J Clin Pathol 2009;131:228-42.
14. Marchiò C, Iravani M, Natrajan R, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008;215:398-410.
15. Rodriguez-Pinilla SC, Rodriguez-Gil Y, Moreno-Bueno G, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype. Am J Surg Pathol 2007;31:501-8.
16. Hayes MJ, Thomas D, Emmons A, et al. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res 2008;14:4038-44.
17. O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology 2008;52:3-10. (Pubitemid 350265178)
18. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
19. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74. (Pubitemid 32878711)
20. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010;220:263-80.
21. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6. (Pubitemid 34130608)
22. Geyer FC, Lopez-Garcia MA, Lambros MB, et al. Genetic characterisation of breast cancer and implications for clinical management. J Cell Mol Med 2009;13:4090-103.
23. Gruvberger S, Ringner M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-84. (Pubitemid 32762524)
24. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23. (Pubitemid 36842560)
25. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
26. Reis-Filho JS, Westbury C, Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 2006;59:225-31. (Pubitemid 43344880)
27. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and managment: divide and conquer. Cancer Invest 2008;26:1-10.
28. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85. (Pubitemid 41170290)
29. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74. (Pubitemid 39100473)
30. Westburry CB, Reis-Filho JS, Dexter T, et al. Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-α (ER α) in response to therapeutic radiation. J Pathol 2009;219:131-40.
31. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: How special are they? Mol Oncol 2010;4:192-208.
32. Oakley GJ III, Tubbs RR, Crowe J, et al. HER-2 amplification in tubular carcinoma of the breast. Am J Clin Pathol 2006;126:55-8. (Pubitemid 44025071)
33. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer in a subgroup of basal breast cancers. Cancer Res 2006;66:4636-44.
34. Andre F, Domont J, Delaloge S. What can breast cancer molecular sub-classification add to conventional diagnostic tools? Annals of Oncology 2007;18(Suppl 9):ix-33-6.
35. Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic subgroup of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007;9:R24.
36. Kaya H, Bozkurt SU, Erbarut I, et al. Apocrine carcinomas of the breast in Turkish women: Hormone receptors, c-erbB-2 and p53 immunoexpression. Pathol Res Pract 2008;204:367-71.
37. Tanaka K, Imoto S, Wada N, et al. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. Breast J 2008;14:164-8. (Pubitemid 351341839)
38. Celis JE, Cabezòn T, Moreira JM, et al. Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. Mol Oncol 2009;3:220-37.
39. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009;117:273-80.
40. Weigelt B, Geyer FC, Horlings HM, et al. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol 2009;22:1401-14.
41. Vranic S, Tawfik O, Pallazo J, et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010;23:644-53.
42. Sabatier R, Finetti P, Cervera N, et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 2011;126:407-20.
43. Matos I, Dufloth R, Alvarenga M, et al. P63, cytokeratin 5 and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virch Arch 2005;447:688-94. (Pubitemid 41571183)
44. Lakhani S, Ellis IO, Schnitt SJ, et al. WHO classification of Tumours of the Breast. Lyon: International Agency for Research in Cancer (IARC), 2012.
45. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for immunoistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:48-72.
46. Turashvili G, McKinney SE, Goktepe O, et al. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Mod Pathol 2011;24:64-81.
47. Sousa B, Paredes J, Milanezi F, et al. P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Hist Histopathol 2010;25:963-74.
48. Milanezi F, Carvalho S, Schmitt F. EGFR/HER2 in breast cancer: a biological approach for a molecular diagnosis and therapy. Expert Rev Mol Diagn 2008;8:417-34. (Pubitemid 351962088)
49. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
50. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216:141-50.
51. Vu-Nishino H, Tavassoli FA, Ahrens WA, et al. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2005;62:1040-7. (Pubitemid 40884416)
52. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-71. (Pubitemid 41032603)
53. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010;21:488-92.
54. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11:174-83.
55. Nishimura R, Osako T, Okumura Y, et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 2010;17:269-75.